Skip to main
EOLS

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Evolus Inc. reported a 3.7% year-over-year increase in total net revenue, reaching $69.4 million, primarily due to higher volumes of Jeuveau and a successful launch of the Evolysse dermal filler line. The company anticipates Evolysse will contribute approximately 10-12% to its 2025 top-line guidance, reflecting positive initial demand from younger consumers who are increasingly favoring aesthetic treatments. Additionally, the management's confidence in Jeuveau's potential to gain market share, supported by its superior effectiveness, along with the promising growth trajectory in the cash-pay aesthetic market, bolsters the overall outlook for Evolus.

Bears say

Evolus has experienced a decline in adjusted gross margin, dropping from 71.5% to 66.5%, primarily due to a higher proportion of international sales and introductory pricing aimed at increasing product adoption. The company has also revised its 2025 net revenue guidance downward to $295-$305 million, reflecting a significant reduction in expected growth from a previous forecast of 30%-33% to just 11%-15%. Additionally, the overall market for aesthetic procedures has been under pressure, evidenced by a reported decline in procedure volumes and a 13% quarter-over-quarter drop in Jeuveau sales, marking the first year-over-year decline since its inception in 2019.

Evolus (EOLS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Buy based on their latest research and market trends.

According to 5 analysts, Evolus (EOLS) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.